Inicio > BIGG > Resultado de la búsqueda

    Resultados: 2

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    England. National Institute for Health and Care Excellence.
    This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
    Neoplasias de la Próstata/tratamiento farmacológico, Mutación/efectos de los fármacos, Proteína BRCA1, Antineoplásicos Hormonales/uso terapéutico
    Texto completo

    Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

    England. National Institute for Health and Care Excellence.
    Evidence-based recommendations on mobocertinib (EXKIVITY) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. Commercial arrangement There is a simple discount patient access scheme for mobocertinib. NHS organisations ca...
    Inhibidores de Proteínas Quinasas/uso terapéutico, Neoplasias Pulmonares/tratamiento farmacológico, Platino (Metal)/uso terapéutico, Mutación/efectos de los fármacos, Factor de Crecimiento Epidérmico/antagonistas & inhibidores
    Texto completo